Edition:
United Kingdom

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

26.62USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$26.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
75,403
52-wk High
$27.35
52-wk Low
$7.81

Select another date:

Thu, Nov 9 2017

BRIEF-Concert Pharmaceuticals reports Q3 earnings per share $5.61

* Concert Pharmaceuticals reports third quarter 2017 financial results and provides company update

BRIEF-Concert Pharmaceuticals announces completion of enrollment in First Cohort of CTP-543 phase 2a trial

* Concert Pharmaceuticals Inc announces completion of enrollment in First Cohort of CTP-543 phase 2a trial

BRIEF-Concert Pharma pays total of $30.8 mln to Hercules Capital

* Concert Pharmaceuticals- ‍on Sept 7, paid total of $30.8 million to hercules capital outstanding under loan and security agreement with Hercules dated June 8

BRIEF-Concert Pharmaceuticals reports Q2 loss per share $0.58

* Concert Pharmaceuticals reports second quarter 2017 financial results and provides company update

BRIEF-Vertex and Concert Pharmaceuticals complete asset purchase agreement

* Vertex and Concert Pharmaceuticals complete asset purchase agreement for CTP-656 Source text for Eikon: Further company coverage:

BRIEF-Concert Pharmaceuticals terminates Hart-Scott-Rodino act waiting period for CTP-656 asset purchase agreement

* Concert Pharmaceuticals announces termination of the Hart-Scott-Rodino act waiting period for CTP-656 asset purchase agreement with Vertex

FDA lifts hold on Concert Pharma's study testing hair loss drug

Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) lifted a clinical hold on a trial testing its therapy for alopecia areata, a type of hair loss.

UPDATE 1-FDA lifts hold on Concert Pharma's study testing hair loss drug

July 10 Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) lifted a clinical hold on a trial testing its therapy for alopecia areata, a type of hair loss.

BRIEF-Concert Pharma says FDA lifts clinical hold on its clinical trial with CTP-543

* Fda lifts clinical hold on concert pharmaceuticals clinical trial with ctp-543

FDA lifts hold on Concert Pharma's hair loss drug

July 10 Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration lifted the clinical hold on a mid-stage study testing its drug to treat alopecia areata, a type of hair loss.

Select another date: